The results of previous study analyzing genetic alterations across various sarcoma types through targeted sequencing to identify effective targeted agents revealed that the most prevalent targetable changes involved cell cycle control, TP53, receptor tyrosine kinase/PI3K/RAS pathways, and epigenetic regulators (31). This evidence concerns the gene NTRK1 and sarcoma.